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Integrin β3 is seen as a key anti-angiogenic target for cancer treatment due to 38 
its expression on neovasculature, but the role it plays in the process is complex; 39 
whether it is pro- or anti-angiogenic depends on the context in which it is 40 
expressed.  To understand precisely β3’s role in regulating integrin adhesion 41 
complexes in endothelial cells, we characterised, by mass spectrometry, the β3-42 
dependent adhesome.  We show that depletion of β3-integrin in this cell type 43 
leads to changes in microtubule behaviour that control cell migration. β3-44 
integrin regulates microtubule stability in endothelial cells through Rcc2/Anxa2 45 
driven control of active Rac1 localisation.  Our findings reveal that angiogenic 46 
processes, both in vitro and in vivo, are more sensitive to microtubule targeting 47 
agents when β3-integrin levels are reduced. 48 
 49 
Introduction 50 
Angiogenesis, the formation of new blood vessels from those that already exist, plays 51 
an essential role in tumour growth [1]. As such, targeting angiogenesis is seen as 52 
crucial in many anti-cancer strategies [2]. Therapies directed against vascular 53 
endothelial growth factor (VEGF) and its major receptor, VEGF-receptor-2 (VEGFR2), 54 
whilst effective in a number of cancers, are not without side-effects due to the role this 55 
signaling pathway plays in vascular homeostasis [3]. Fibronectin (FN)-binding 56 
endothelial integrins, especially αvβ3- and α5β1-integrins, have emerged as 57 
alternative anti-angiogenic targets because of their expression in neovasculature [4, 58 
5]. However, neither global nor conditional knockouts of these integrins block tumour 59 
angiogenesis long-term [6-8], and clinical trials of blocking antibodies and peptides 60 
directed against these extracellular matrix (ECM) receptors have been disappointing 61 
[9, 10]. To gain novel insight into how αvβ3-integrin regulates outside-in signal 62 
transmission [11], we have undertaken an unbiased analysis of the molecular 63 
composition of the mature endothelial adhesome, and profiled changes that occur 64 
when β3-integrin expression is manipulated. In so doing, we have uncovered β3-65 
integrin dependent changes in microtubule behaviour that regulate cell migration. 66 
 67 
Results and Discussion 68 
The isolation and analysis of integrin adhesion complexes (IACs) by mass-69 
spectrometry (MS) is difficult because of the low affinity and transient nature of the 70 
molecular interactions occurring at these sites. However, using cell-permeant chemical 71 
crosslinkers improves recovery of IAC proteins bound to either FN-coated microbeads 72 
[12] or plastic dishes [13]. These advances have led to the characterisation of IACs 73 
from a number of cell types. Whilst a core consensus adhesome (the network of 74 
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structural and signaling proteins involved in regulating cell-matrix adhesion [14]) can 75 
be defined [12], the composition and stoichiometry of the meta-adhesome depends on 76 
the cell-type being analysed, the integrin-receptor repertoire expressed by that cell 77 
type, and on any imposed experimental conditions. To examine the composition of the 78 
endothelial adhesome we isolated lung microvascular endothelial cells (ECs) from 79 
C57BL6/129Sv mixed background mice and immortalised them with polyoma-middle-80 
T-antigen by retroviral transduction [15]. As our main interest was in establishing how 81 
β3-integrin influences the endothelial adhesome, we adhered cells to FN for 90 82 
minutes, which allows β3-rich (mature) focal adhesions (FAs) to form [16]. To 83 
distinguish integrin-mediated recruitment of proteins from non-specific background, we 84 
also plated cells on poly-L-lysine (PLL) as a negative control (adhesion to PLL does 85 
not depend on integrins). Visualisation of neuropilin-1 staining in whole cells showed 86 
that this protein, which we previously demonstrated is present in the mature EC 87 
adhesome [17], co-localises with talin-1 in FAs when cells are plated on FN, but not 88 
PLL (Fig. 1A). For all proteomics experiments, we crosslinked FAs using the cell 89 
permeant and reversible cross-linkers DPDPB and DSP (see materials and methods) 90 
for 5 minutes. Cells were lysed and subjected to a high sheer flow water wash to 91 
remove non-crosslinked material. Crosslinking was reversed, and samples were 92 
precipitated and concentrated for analyses. Prior to MS, samples were quality 93 
controlled by SDS/PAGE and silver-staining to ensure efficient removal of non-94 
crosslinked material had occurred (Fig. 1B). 95 
 96 
Label-free proteomic analyses of the FN + VEGF, FN, and PLL adhesomes (Fig. 1C; 97 
Table EV1) initially detected and quantified 1468 proteins. Stringent filtering, requiring 98 
proteins to be detected in all 3 repeats of at least one condition, left 1064 proteins – a 99 
high confidence dataset that was used to define the endothelial adhesome. 100 
Hierarchical clustering based on average Euclidian distance identified 12 clusters (A-101 
L) which could be considered VEGF-enriched proteins (A-C), FN-enriched (D-F), and 102 
PLL-enriched (G-L). Fisher’s exact test enrichment analysis was carried out to identify 103 
which pathway, process, or component proteins within these clusters belong to using 104 
Gene Ontology annotations. Cell projection (GOCC, p=8.62 x 10-5) and microtubule 105 
(GOCC, p=1.6 x 10-4) categories were significantly enriched when cells were treated 106 
with growth factor, suggesting they are important in VEGF-mediated processes. 107 
Leukocyte trans-endothelial migration (KEGG, p=9.71 x 10-5) proteins were enriched 108 
in the FN adhesome, but not in the VEGF-stimulated adhesome, suggesting our cells 109 
represent quiescent vasculature without VEGF-stimulation. This same category 110 
contains many endothelial specific proteins (e.g. VE-cadherin, Cdh5), further 111 
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confirming that the cells have an endothelial identity. Focal adhesion (KEGG, 112 
p=9.31x10-7) proteins were enriched in the FN adhesome but depleted in the PLL 113 
adhesome, confirming the success of the adhesome enrichment process, MS, and 114 
downstream analysis. Other adhesion/migration associated categories: focal adhesion 115 
(GOCC, p=5.99 x 10-5), cell projection (GOCC, p=3.03 x 10-5), cell adhesion (GOBP, 116 
p=1.61 x 10-6) and lamellipodium (GOCC, p=1.38 x 10-4) were depleted in the PLL 117 
adhesome. 118 
 119 
To test the consequences of excluding β3-integrin from the EC adhesome, we decided 120 
to profile changes in β3-heterozygous (β3HET) ECs, which carry one wild-type allele 121 
of β3-integrin, and one knockout allele. These cells express 50% wild-type levels of 122 
β3-integrin.  As in previous studies, we decided to use β3HET cells for these initial 123 
analyses, rather than β3-integrin knockout (β3NULL) cells, hypothesising this would 124 
circumvent potential developmental changes arising from the complete loss of the 125 
protein, which we felt might confound quantitative interpretations of the EC adhesome; 126 
we have shown these cells are a good model for studying the role of αvβ3-integrin in 127 
cell migration, whilst evading changes arising from the complete loss of the integrin on 128 
both alleles (e.g. up-regulated total VEGFR2 expression) [17]. Both wild-type (β3WT) 129 
and β3HET ECs adhere equally to saturating concentrations (10 µg/ml) of FN (see 130 
Ellison et al., 2015 [17]). To compare the size distribution of FAs between β3WT and 131 
β3HET ECs (which might affect the stoichiometry of components in the adhesome), 132 
we seeded cells for 90 minutes on FN, immunostained for paxillin, and measured FA 133 
area; we noted no differences in the percentage of FA size distributions between the 134 
two genotypes (Fig. 2A). Therefore, MS analyses comparing the adhesome between 135 
β3WT and β3HET ECs were performed (Fig. 2B; Table EV2). Enrichment analysis 136 
showed a depletion of cytoskeletal components (GOCC, p = 4.73 x 10-5) in the β3WT 137 
adhesome when compared with the β3HET adhesome, despite the enrichment of 138 
adhesion/migration associated categories previously noted in the FN adhesome of 139 
β3WT ECs (Fig. 1C). Whilst a majority of individual FA components in the mature 140 
adhesome do not change upon β3-integrin depletion, downstream connections to 141 
cytoskeletal components do. We took a particular interest in microtubules (MTs) 142 
because by SAM analysis all detected tubulins were significantly upregulated in the 143 
β3HET adhesome. To confirm this finding by other means, we probed western blots 144 
for α-tubulin and showed a significant increase in FA-enriched samples from β3HET 145 
cells compared with β3WT cells (Fig. 2C).  146 
 147 
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Our findings intimated that αvβ3-integrin drives MT localisation away from FAs. To 148 
increase the power of our downstream mechanistic analyses, we felt it appropriate to 149 
now also include β3NULL ECs in our studies. We examined MT organisation in β3WT, 150 
β3HET, and β3NULL ECs by immunolabeling for α-tubulin in whole cells (Fig. 3A). No 151 
gross changes in cell microtubule arrays were observed. Furthermore, total cellular 152 
levels of α-tubulin were similar across all three genotypes (Fig. 3B). However, co-153 
localisation of MTs at peripheral FAs was greater in β3HET and β3NULL ECs, 154 
compared to β3WT ECs, as was extension into lamellipodea (Fig. 3C; for an example 155 
of quantification of the latter, see Fig. EV1). Overall, the findings suggest that β3-156 
integrin limits the targeting of MTs to FAs.  157 
 158 
Given that MTs can drive FA turnover, and thus cell migration [18], we next tested 159 
whether EC migration is differentially sensitive to microtubule targeting agents (MTAs) 160 
in β3HET and β3NULL ECs. For each MTA examined, we first determined the dose of 161 
the compound that allowed 90 percent survival of β3WT ECs (see materials and 162 
methods), and then tested the effects of this dose on random migration in β3WT, 163 
β3HET, and β3NULL cells (Fig. 3D; raw migration data shown in Fig. EV2). Random 164 
migration was affected by MT stabilisers (Paclitaxel, Epothilone B) in cells of all three 165 
genotypes, However, β3WT ECs were insensitive to the MT destabilisers tested 166 
(Colchicine, Mebendazole, Fosbretabulin) and the mechanistically unique MTA 167 
Eribulin (which functions through an end poisoning mechanism [19]), whilst β3HET 168 
and β3NULL ECs generally showed a sensitivity to all classes of compounds tested. 169 
We extended these types of analyses in vivo to examine the effects of Eribulin and 170 
Fosbretabulin on tumour growth and angiogenesis. We chose these two MTAs as they 171 
are well tolerated in mice [20, 21] and used clinically in humans. We settled on 172 
suboptimal doses (see materials and methods) that would allow us to observe potential 173 
synergy with endothelial depletion of β3-integrin. β3-integrin-floxed/floxed mice [22] 174 
were bred with Tie1Cre mice [23] to generate β3-integrin-floxed/floxed Cre-positive 175 
animals (Cre-negative littermates were used as controls). CMT19T lung carcinoma 176 
cells were injected subcutaneously and allowed to establish for 7 days, at which point 177 
the MTAs were administered (see materials and methods for dosing regimes). Neither 178 
Eribulin nor Frosbretabulin had any effect on tumour growth in Cre-negative animals 179 
compared with vehicle treated animals, but tumour growth was reduced in MTA-treated 180 
Cre-positive animals (Fig. 3E). Analysis of tumours by immunostaining for blood 181 
vessels showed a reduction in intratumoral microvascular density only in sections from 182 
MTA-treated Cre-positive animals (Fig. 3F). These studies suggested that the loss of 183 
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endothelial β3-integrin sensitises angiogenic responses to MT destabilisers both in 184 
vitro, and in vivo. 185 
 186 
The increased sensitivity to destabilising MTAs suggested to us that there is an 187 
increased population of stable MTs in β3HET and β3NULL ECs compared with their 188 
wild-type counterparts. We explored this premise by exposing ECs to cold 189 
temperatures (which destabilises MTs), washing out tubulin monomers [24], followed 190 
by immunolabelling for α-tubulin. We noted elevated stable MTs in both β3HET and 191 
β3NULL cells (Fig. 4A).  Re-introducing β3-integrin into β3NULL cells restored MT 192 
sensitivity to cold; MTs were more sensitive to cold treatment in NULL cells expressing 193 
full-length human β3-integrin, than MTs in cells transfected with an empty vector 194 
control (Fig. EV3).  We also measured MT stability biochemically by extracting both 195 
cold-sensitive and cold-stable MTs from the same sample of cold-treated cells and 196 
western blotting for α-tubulin (Fig. 4B). On whole, β3HET and β3NULL ECs showed 197 
decreased cold-sensitive and increased cold-stable MTs compared with β3WT ECs. 198 
 199 
To gain further mechanistic insight into how β3-integrin at FAs might be regulating MT 200 
function, we delved deeper into our β3-dependent adhesome data. We noted that Rcc2 201 
clusters with β3-integrin in the β3WT adhesome, but is significantly decreased in that 202 
of β3HET ECs. Rcc2 (also known as telophase disk protein of 60 kDa, TD-60) has 203 
previously been shown to associate with integrin complexes [25] and to regulate MTs 204 
[26]. We therefore examined whether Rcc2 was regulating MT stability in ECs. 205 
Knocking down Rcc2 by siRNA in β3WT ECs elicited a significant increase in cold-206 
stable MTs (Fig. 5A; see Fig. EV4 for representative MT staining). This finding 207 
suggested to us that Rcc2 plays a β3-dependent role in regulating MTs in ECs, but 208 
does not do so in isolation. We therefore cross-referenced our adhesome data with an 209 
Rcc2 pull-down assay performed from HEK-293T cells (Table EV3) [27]. Some 210 
obvious potential candidates (e.g. Coronin-1C) were present in both the β3WT and 211 
β3HET adhesomes, but at the same level, so were ruled out from further analysis. 212 
However, annexin-a2 (Anxa2) co-precipitates with Rcc2 in HEK-293T cells and, like 213 
Rcc2, was reduced in the β3HET adhesome. Therefore, we examined whether Anxa2 214 
was also regulating MT stability in ECs via siRNA-mediated knockdown. Like Rcc2 215 
knockdown, even a relatively small (~30%) Anxa2 knockdown in β3WT ECs elicited a 216 
significant increase in cold-stable MTs (Fig. 5B; see Fig. EV4 for representative MT 217 
staining).  Moreover, a double knockdown of both targets led to an additive increase 218 
in cold-stable MTs in β3WT ECs (Fig. EV4). 219 
 220 
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Both Rcc2 [25, 27] and Anxa2 [28] have been identified as regulators of Rac1, and 221 
work by a number of groups has demonstrated that cortical Rac1 activity promotes MT 222 
stability [29-31]. Because total Rac1 stoichiometry was unchanged when comparing 223 
β3WT and β3HET EC adhesomes, we hypothesised that Rcc2/Anxa2-dependent 224 
alterations in Rac1 activity were responsible for altered MT stability in β3HET and 225 
β3NULL ECs. First, we tested the premise that Rac1 plays a differential role in 226 
regulating MT stability in β3WT and β3-depleted ECs by testing the effects of the Rac1 227 
inhibitor NSC23766. NSC23766 had no effect on MT stability in β3WT cells, but the 228 
number of cold stable MTs in both β3HET and β3NULL ECs was reduced in the 229 
presence of the inhibitor (Fig. 5C; see Fig. EV4 for representative MT staining). We 230 
also demonstrated that the increases observed in MT stability upon Rcc2 or Anxa2 231 
knockdown were abrogated in the presence of NSC23766 (Fig. EV5), suggesting that 232 
both proteins regulate MT stability in ECs in a Rac1-dependent manner. 233 
 234 
Rcc2 has previously been reported to limit the activation of both Rac1 and Arf6 [25]. 235 
Indeed, Rcc2 can guide mesenchymal cell migration by trafficking Rac1 and controlling 236 
its exposure to GEFs [27]. We therefore tested whether there were differences in 237 
Rcc2/Anxa2/active-Rac1 associations between β3WT and β3-depleted ECs. First, we 238 
examined total cellular levels or Rac1 and showed they were equivalent in all three 239 
cell lines (Fig. 5D). PAK-PBD pull-downs of GTP-bound Rac1 showed co-association 240 
of all three proteins in β3WT, β3HET and β3NULL ECs (Fig. 5E), so we concluded that 241 
changes in Rac1 activity alone were not responsible for alterations in MT stability in 242 
β3-depleted cells. Humphries et al. showed that Rcc2 is recruited to α5β1-FN 243 
complexes but not α4β1-Vcam1 (vascular cell adhesion molecule-1) complexes in 244 
cells expressing both α4- and α5-integrins [25]. Thus, we also tested associations 245 
between Rcc2, Anxa2 and α5-integrin in β3WT and β3-depleted ECs by PAK-PBD 246 
pull-downs. Rcc2, Anxa2, β3-integrin and α5-integrin were pulled down with Rac1-GTP 247 
in β3WT ECs. Rcc2, Anxa2 were also pulled down with Rac1-GTP in β3HET and 248 
β3NULL ECS, whilst β3-integrin-Rac1-GTP associations were lost and α5-integrin-249 
Rac1-GTP associations were increased (Fig. 5E). Given the stoichiometry of α5-250 
integrin in the β3-depleted adhesome is unchanged compared to the β3WT adhesome 251 
(Fig. 2) whilst Rcc2 and Anxa2 levels are decreased, we speculated that a substantial 252 
proportion of the observed increase in Rcc2/Anxa2/active-Rac1/Itga5 associations in 253 
β3-depleted cells occurs away from β3-rich FAs, perhaps in recycling endosomes.  254 
Endocytic trafficking of Rac1 is required for the spatial restriction of signaling during 255 
mammalian cell migration [32].  In support of this hypothesis, we demonstrated a 256 
redistribution of Rac1-GTP in β3-depleted ECs using a Raichu-Rac1 biosensor (Fig. 257 
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5F); compared to β3WT ECs, a substantial proportion of active Rac1 in β3HET and 258 
β3NULL cells appeared cytoplasmic. This redistribution of active Rac1 appeared to be 259 
independent of the total level of active Rac1 present in the cells; active Rac1 levels 260 
were only noticeably elevated in β3HET cells (Fig. 5F). 261 
 262 
By mining the FN-β3-integrin EC adhesome, not only have we generated a valuable 263 
tool for the integrin and angiogenesis communities, we have also utilised the data to 264 
uncover a novel role for β3-integrin in regulating MT function/stability during EC 265 
migration. We previously showed that endothelial Rac1 is only required for tumour 266 
growth and angiogenesis when β3-integrin is absent [33], but the underlying 267 
mechanism for this observation has remained unclear. Our working hypothesis is that 268 
engagement of αvβ3-integrin with FN at mature FAs localises an Rcc2/Anxa2/Rac1 269 
containing complex to these sites, either preventing GTP-Rac1 from participating in 270 
MT stability, or actively destabilising MTs (our experiments do not allow us to 271 
distinguish between these two possibilities), perhaps by controlling its exposure to 272 
GEFs. When αvβ3 is not present, the complex associates with α5β1-integrin instead, 273 
where it now has the opposite effect on MTs (see synopsis). This re-positioning of 274 
Rac1 activity means that it plays a role in MT-linked EC migration only when αvβ3 is 275 
not present in mature FAs. There is certainly precedence for β3-integrin regulating 276 
spatial distribution of signaling pathway components in cells. For example, we 277 
previously showed that β3-integrin plays a role in locally suppressing β1-integin in 278 
fibroblasts to promote persistent cell protrusion and migration by regulating 279 
interactions between vasodilator-stimulated phosphoprotein (Vasp) and Rap1-GTP-280 
interacting adaptor molecule (Apbb1ip/RIAM) [34]. Moreover, MTs have recently been 281 
shown to target active β1-integrins [35]. Thus, it will be particularly pertinent to next 282 
determine the full composition of the Rcc2/Anxa2/Rac1-GTP complex as many of the 283 
proteins that might be suspected to play a role in MT capture (e.g. Clip170 and Clasps) 284 
do not appear to be present in the EC adhesome [36]; to gain a full picture of how MT 285 
stability/FA targeting are regulated in ECs, it will also be essential to establish how this 286 
complex behaves in α5β1-deficient ECs.  287 
 288 
Finally, it is worth considering how changes in levels of integrin expression might affect 289 
the cellular responses we have examined.  Whilst, in general (e.g. sensitivity to MTAs, 290 
including cold), β3HET and β3NULL cells behaved similarly in the assays we 291 
employed, there are two notable differences: (1) β3NULL cells showed increased MT 292 
targeting to lamellipodia, compared to β3HET cells (Fig. 3C), which might suggest 293 
altered MT dynamics between the two genotypes. It will be important to examine 294 
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microtubule dynamics in greater detail (e.g.  rates of growth, catastrophe, and rescue) 295 
with changes in integrin expression patterns/levels. (2) On fibronectin, β3HET cells 296 
showed increased Rac1-GTP levels compared to β3NULL cells (Fig. 5). This might 297 
relate to the increased total VEGFR2 levels noted in β3NULL [37] but not β3HET [17] 298 
cells. If VEGFR2 is playing a role here, we speculate it is separate from its known 299 
interactions with αvβ3-integrin.  VEGFR2 and αvβ3-integrin interactions are 300 
augmented on vitronectin [38], and we do not detect VEGFR2 in our FN-dependent 301 
EC adhesome (Fig. 1).  Notwithstanding, our findings suggest that once effective αvβ3-302 
integrin antagonists are available (e.g. ProAgio [39]), they may be particularly useful 303 
as anti-angiogenic agents when used in combination with already approved MTAs, 304 
such as Eribulin. 305 
 306 
Materials and Methods 307 
Reagents 308 
Unless otherwise stated all chemicals used were purchased from Sigma-Aldrich 309 
(Poole, UK). Vascular endothelial growth factor (mouse VEGF-A164) was made in 310 
house according to Krilleke et al. [40]. 311 
 312 
Animals 313 
All animals were on a mixed C57BL6/129 background. Littermate controls were used 314 
for all in vivo experiments. All animal experiments were performed in accordance with 315 
UK Home Office regulations and the European Legal Framework for the Protection of 316 
Animals used for Scientific Purposes (European Directive 86/609/EEC). 317 
 318 
Mouse endothelial cell isolation and culture 319 
Mouse lung ECs were isolated from adult mice on a mixed C57BL6/129 background 320 
as per Reynolds and Hodivala-dilke [41] then subsequently immortalised and cultured 321 
as per Ellison et al. [17].  The cell lines used in the studies presented here were cross-322 
referenced to a pure C57BL6 genetic background via a 384 single nucleotide 323 
polymorphism panel (Charles River Genetic Testing Services, Wlmington, MA, USA). 324 
These analyses showed: β3WT=91.99% C57BL6; β3HET=93.03% C57BL6; 325 
β3NULL=44.75% C57BL6. 326 
 327 
Adhesion Assay 328 
96 well plates were coated in 10 µg ml-1 fibronectin (FN) in phosphate buffered saline 329 
(PBS) overnight at 4°C then blocked with 1% bovine serum albumin (BSA) in PBS for 330 
1 hour at room temperature. 20,000 cells were seeded into each well and allowed to 331 
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adhere for 90 minutes. Cells were then washed with PBS with 1 mM MgCl2 and 1 mM 332 
CaCl2 3 times to remove non-adherent cells and fixed with 4% paraformaldehyde 333 
(PFA) for 10 minutes at room temperature. After a further PBS wash, cells were stained 334 
with 1% methylene blue in 10 mM borate buffer pH 8.5/50% Methanol for 30 minutes 335 
at room temperature. Excess stain was removed with RO water before a 50% 0.1 M 336 
HCl/50% Ethanol destain solution was used for 10 minutes at room temperature. The 337 
destain solution was then moved to a new plate and read absorbance was measured 338 
at 630 nm. 339 
 340 
Focal Adhesion Enrichment 341 
Focal-adhesion enrichment was carried out as described in Ellison et al. [17] and 342 
Schiller et al. [13]. A small amount of each focal adhesion sample generated was 343 
quality controlled by running a 10% SDS-PAGE gel followed by silver staining (Pierce 344 
TM
 Silver Stain Kit, ThermoFisher Scientific, Cramlington, UK). Good quality samples 345 
were then analysed by western blotting or mass spectrometry. 346 
 347 
Mass Spectrometry (MS) 348 
Mass spectrometry was carried out by the Fingerprints Proteomics Facility (Dundee 349 
University, Dundee, UK) as per Schiller et al. [13]. Peptides were identified and 350 
quantified using MaxQuant [42] software using the Andromeda peptide database. To 351 
achieve label-free quantitative results, three biological repeats were pooled and each 352 
of these pooled samples was analysed via three technical repeats through the 353 
spectrometer. 354 
 355 
MS Statistical Analysis 356 
All mass spec analysis was performed using the Perseus [43] bioinformatics toolbox 357 
for MaxQuant. Statistical significance was identified using the Significance Analysis of 358 
Microarrays (SAM) method [44]. Unsupervised hierarchical clustering was performed 359 
using Perseus’ built in tools. KEGG and GO annotations were obtained from the mouse 360 
annotations package via Perseus (downloaded 20/06/2015) and used to identify 361 
angiogenesis, cytoskeleton and focal adhesion related genes. 362 
 363 
Random Migration 364 
24 well plates were coated with 10 µg ml-1 FN in PBS overnight at 4°C and then blocked 365 
with 1% BSA for 1 hour at room temperature. 10,000 ECs were seeded per well and 366 
allowed to recover overnight.  Media was then replaced with media containing one of 367 
the following microtubule targeting agents (MTAs –from Abcam, Abingdon, UK, unless 368 
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otherwise noted): Paclitaxel 5nM, Epothilone B 1nM, Colchine 10µM, Mebendazole 369 
0.4µM, Fosbretablin 0.5µM or Eribulin 1µM (a kind gift from Katherine Weilbaecher, 370 
Washington University, MO, USA); DMSO was used as a vehicle control. A phase 371 
contrast image was taken of each well every 20 minutes using an inverted Axiovert 372 
(Zeiss) microscope for 15 hours at 37°C and 5% CO2. The ImageJ plugin MTrackJ [45] 373 
was then used to manually track individual cells and the speed of random migration 374 
was calculated. 375 
 376 
Microtubule Stability Assays 377 
Microtubule cold stability assays were carried out as described in Ochoa et al. [24]. 378 
Briefly: 750,000 ECs were seeded per well of a 6 well plate (FN coated/BSA blocked 379 
as described earlier) and allowed to adhere for 75 minutes at 37°C before being moved 380 
to ice for 15 minutes. Cells were washed with PBS and then 100µl of PEM buffer (80 381 
µM PIPES pH 6.8, 1 mM EGTA, 1 mM MgCl2, 0.5% Triton X-100 and 25% (w/v) 382 
glycerol for 3 minutes. A second brief wash was performed with 50µl PEM buffer. All 383 
PEM buffer was collected and pooled together with 150µl EB buffer (3% SDS, 60 mM 384 
Sucrose, 65 mM Tris-HCL pH 6.8) at 2X concentration (representing cold soluble 385 
microtubules). Remaining material on the plate was then extracted using 300µl of EB 386 
buffer (representing cold stable microtubules). Samples were then used in western 387 
blotting analysis. 388 
 389 
Additionally, the same procedure was used on ECs adhered to FN coated/BSA 390 
blocked coverslips (acid washed and bake-sterilised before coating). They were 391 
treated as above except after PEM washing the slides were immediately immersed in 392 
-20°C 100% methanol for 20 minutes. Coverslips were then used in immunolabelling 393 
analysis. 394 
 395 
In vivo tumour growth assays 396 
The syngeneic mouse lung carcinoma cell line (derived from C57BL6 mice) CMT19T 397 
was used to grow subcutaneous tumours in β3 fl/fl Tie1Cre positive (and Cre negative 398 
littermate control) mice. Under anaesthetic, mice were injected subcutaneously in the 399 
flank with 1 x 106 cells. Tumours then grew for 7 days, at which point they were 400 
palpable through the skin, before the mice were treated with: (1) 0.15mg kg-1 Eribulin 401 
(kindly provided by Katherine Weilbaecher, Washington U) intravenously once a week 402 
for 2 weeks, or (2) 50mg kg-1 Fosbretabulin intraperitoneally every 4 days. After 21 403 
days mice were culled and tumours were excised, photographed and measured for 404 
volume using a digital caliper. Tumours were bisected along the midline, fixed 405 
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overnight in 4% paraformaldehyde, preserved for several days in cryoprotectant (20% 406 
sucrose, 2% poly(vinylpyrrolidone) in PBS), embedded in gelatin (8% gelatin, 20% 407 
sucrose, 2% poly(vinylpyrrolidone) in PBS) before being snap frozen and stored at -408 
80°C. 409 
 410 
Focal-adhesion and microtubule tracking 411 
1 x 106 ECs were transfected with a GFP-tagged paxillin cDNA expression construct 412 
(provided by Maddy Parsons, KCL) by nucleofection. Cells were allowed to recover 413 
overnight before a fraction were seeded on FN coated/BSA blocked coverslips (acid 414 
washed and baked before coating) and adhered for 3 hours. Cells were then treated 415 
with 100nM SiRTubulin (Cytoskeleton Inc CY-SC002) and 1µM Verapamil overnight. 416 
Coverslips were imaged individually on an Axiovert (Zeiss) inverted microscope where 417 
one image of a GFP positive cell was taken every minute for 30 minutes at 37°C and 418 
5% CO2 in green and far-red channels. During imaging media was replaced with 419 
Phenol-red free OptiMEM® + 2% FBS containing 100nM SiRTubulin and 1µM 420 
Verapamil. The total area of adhesive fronts was assessed by measuring the growth 421 
of paxillin-GFP positive areas between the 1st and 30th image and then the number of 422 
microtubules that entered the adhesive front over 30 minutes were counted. 423 
 424 
Western Blotting 425 
For western blot analysis of total tubulin levels. ECs were seeded at 750,000 per well 426 
of a FN coated/BSA blocked 6 well plate and allowed to adhere for 90 minutes before 427 
being lysed in EB buffer. For the microtubule stability assay and focal adhesion 428 
enrichment samples were prepared as above. 20µg from each sample was loaded 429 
onto 10% polyacrylamide gels then transferred to a nitrocellulose membrane and 430 
incubated for 1 hour in 5% milk powder in PBS with 0.1% Tween 20 (PSBTw) followed 431 
by overnight incubation in primary antibody diluted 1:1000 in 5% BSA in PBSTw at 432 
4°C. Primaries used were against integrin beta 3 (Cell Signalling 4702), alpha-tubulin 433 
(Abcam 7291), Gapdh (Abcam 9484), Rcc2 (Abcam 70788), Hspa1a (clone B-6 Santa 434 
Cruz Biotechnology), Anxa2 (Abcam 41803), and Itga5 (Cell Signalling 4705). The 435 
membranes were then incubated with the appropriate horseradish peroxidase (HRP)-436 
conjugated secondary antibody (Dako) diluted 1:2000 in 5% milk in PBSTw for 1 hour 437 
at room temperature. The blot was visualised using Piece® ECL Western Blotting 438 
Substrate kit (ThermoFisher) and chemiluminescence detected on a Fujifilm LAS-3000 439 
darkroom (Fujifilm UK Ltf, Beford, UK). 440 
 441 
 442 
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Immmunolabelleing cells 443 
20,000 ECs were seeded onto FN coated/BSA blocked coverslips and adhered for 90 444 
minutes before being washed with PBS and immersed in -20°C methanol for 20 445 
minutes. Alternatively, cells were prepared as per the microtubule stability assay 446 
protocol above. Coverslips were then washed with PBS, blocked for 10 minutes at 447 
room temperature with 0.5% BSA, 1% goat serum in PBS with 0.25% Triton X-100 and 448 
incubated with primary antibody diluted 1:250 in PBS for 1 hour at room temperature. 449 
After subsequent PBS washes the coverslips were incubated with Alexa-Fluor® 450 
conjugated secondary antibodies raised in donkey (Fisher Scientific) diluted 1:500 in 451 
PBS. Coverslips were washed again in PBS before being mounted onto slides using 452 
Prolong Gold® with DAPI (Fisher Scientific). Primaries used were anti-alpha-tubulin 453 
(Abcam 52866), anti-paxillin (Abcam 32084) anti-talin (Sigma T3287), and anti-Nrp1 454 
(R&D Systems AF566). 455 
To quantify microtubule targeting focal adhesions, images were taken of stained cells 456 
using an epifluorescent microtubule then the number of microtubules with an end 457 
overlapping with a focal adhesion were counted for each cell. 458 
Simultaneous Phalloidin (ThermoFisher A12380) and alpha-tubulin staining was 459 
carried out using PHEMO fixation [46]. 460 
 461 
Immunolabelling tissue sections 462 
Five-µm cryosections were prepared from frozen tumours and stained as described 463 
previously [17].  Primaries used were anti-CD31 (R&D Systems AF3628, 1:500) and 464 
alpha-smooth muscle actin (Abcam 5694; 1:1000). Images were acquired on an 465 
Axioplan (Zeiss) epifluorescent microscope. Vessel density (immediately adjacent to, 466 
but not including, the tumour border) was measured by hand in 3 hot-spots per section.  467 
The area of each counted region was calculated using ImageJ.  468 
 469 
siRNA knockdown 470 
Knockdowns of Rcc2 and Anxa2 were achieved using 3µg of Dharmacon ON-471 
TARGETplus SMARTpool siRNA (control smart pool used as knockdown control) per 472 
1 x 106 ECs in an Amaxa Nucleofector II (T-005 setting). Cells were allowed to recover 473 
for 48 hours to allow knockdown to take effect. 474 
 475 
Generation of human β3 integrin expressing cells 476 
1X106 β3NULL endothelial cells were transfected with 10 µg of MfeI (New England 477 
Biolabs, Hitchin, UK) linearized full-length human β3-integrin (see Robinson et al., 478 
2009 [47]) cloned into pcDNA™6.2/C-EmGFP (see Amaxa nucleofections above).  An 479 
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empty vector (EV) was used as a control. Forty-eight hours post-transfection cells were 480 
selected with 10 μg ml-1 of blasticidin (ThermoFisher). Cells surviving 2 weeks were 481 
analysed for β3-integrin expression by western blotting.  482 
 483 
Active Rac1 Pulldown 484 
6 x 106 ECs were seeded onto FN coated/BSA blocked (as described above) 10 cm 485 
plates and allowed to adhere for 90 minutes. Rac1 Activation Magnetic Beads 486 
Pulldown Assay kit (Millipore 17-10393) was then used per manufacturer’s 487 
instructions. Pull-down material was then loaded directly onto a gel for western blotting. 488 
 489 
Rac1 Biosensor analyses 490 
1 x 106 ECs were transfected with 10µg of Raichu-1011X (a gift from Maddy Parsons, 491 
KCL) via an Amaxa Nucleofector II (T-005 setting). Cells were allowed to recover for 492 
48 hours, then plated onto FN coated/BSA blocked (as described above) coverslips 493 
for 90 minutes.  Cells were fixed for 10 min in 4% PFA, then mounted in Prolong Gold® 494 
without DAPI (ThermoFisher). 495 
 496 
Samples for analysis of the Rac FRET biosensor by acceptor photobleaching were 497 
imaged and analysed as previously described [48]. Briefly, images were acquired 498 
using an inverted Nikon A1R laser scanning confocal microscope. The CFP and YFP 499 
channels were excited using the 440nm diode laser and the 514nm argon line 500 
respectively. The two emission channels were split using a 545nm dichroic mirror, 501 
which was followed by a 475-525 nm bandpass filter for CFP and a 530nm longpass 502 
filter for YFP (Chroma). Pinholes were opened to give a depth of focus of 2 µm for 503 
each channel. Scanning was performed on a sequential line-by-line basis for each 504 
channel. The gain for each channel was set to approximately 75 % of dynamic range 505 
(12-bit, 4096 grey levels) and offsets set such that backgrounds were zero. Time-lapse 506 
mode was used to collect one pre-bleach image for each channel followed by 507 
bleaching with a minimum of 20 iterations of the 514nm argon laser line at maximum 508 
power (to bleach YFP). A second post-bleach image was then collected for each 509 
channel. Control non-bleached areas were acquired for all samples in the same field 510 
of view as bleached cells to confirm specificity of FRET detection. Pre- and post-bleach 511 
TFP and Venus images were then imported into Image J for processing. Briefly, 512 
images were smoothed using a 3 x 3 box mean filter, background subtracted and post-513 
bleach images fade compensated. A FRET efficiency ratio map over the whole cell 514 
was calculated using the following formula: (TFPpostbleach-TFPprebleach)/TFPpostbleach. Ratio 515 
values were then extracted from pixels falling inside the bleach region as well as an 516 
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equally sized region outside of the bleach region and the mean ratio determined for 517 
each region and plotted on a histogram. The non-bleach ratio was then subtracted 518 
from the bleach region ratio to give a final value for the FRET efficiency ratio. Data 519 
from images were used only if YFP bleaching efficiency was greater than 70%.  520 
 521 
Statistical Analyses 522 
All statistical tests were performed using GraphPad PrismTM Software.  Significant 523 
differences between means were evaluated by unpaired two-tailed student’s t test. 524 
P<0.05 was considered statistically significant.  Exact P values are shown on figures, 525 
except where P<0.0001; ns= P>0.05. 526 
 527 
Data availability 528 
The mass spectrometry proteomics data have been deposited to the 529 
ProteomeXchange Consortium via the PRIDE [49] partner repository with the dataset 530 
identifier PXD008591. 531 
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 705 
Figure Legends 706 
Figure 1. Defining the FN endothelial adhesome. 707 
A) WT ECs were adhered to fibronectin (top row) or poly-l-lysine (bottom row) coated 708 
coverslips for 90 minutes before fixing and immunostaining for neuropilin-1 (Nrp1-709 
green) and talin-1 (Tln1-red) along with a nuclear stain (DAPI-blue). Scale bar = 10µm. 710 
B) An example silver stain used in the quality control of adhesome samples. 711 
Adhesome enrichment was carried out on 6 x 106 WT ECs on fibronectin (FN), 712 
fibronectin with VEGF (FN + VEGF) or poly-l-lysine (PLL) before acetone precipitation. 713 
After resuspension samples were run on a SDS-PAGE gel along with a whole cell 714 
lysate control and silver stained. 715 
C) Triplicate adhesome samples from WT ECs adhered on fibronectin (FN), fibronectin 716 
with VEGF (FN + VEGF) or poly-l-lysine were sent for quantitative mass spec analysis. 717 
Label free quantification was carried out using MaxQuant followed by analysis in 718 
Perseus. Unsupervised hierarchical clustering (Euclidian distance calculation) was 719 
carried out with red showing highly abundant proteins and green showing low 720 
abundance proteins. 12 significant clusters were automatically identified using a 721 
distance threshold of 3.34 and labelled A-L. Angiogenesis associated proteins were 722 
identified using GOBP annotations (GO:0001525, GO:0002040, GO:0002042, 723 
GO:0016525, GO:0045765, GO:0045766) and are displayed in the table along with 724 
their associated cluster. 725 
 726 
Figure 2. Analysis of the β3-integrin dependent adhesome. 727 
A) Distribution of adhesion size classes (0-2µm, 2-10µm; >10µm) in β3WT versus 728 
β3HET endothelial cells (n=1400 FAs per genotype; 2 independent experiments).  729 
B) Visual representation of the significant analysis of microarrays (SAM) method as a 730 
volcano plot for β3WT and β3HET samples (n=3). T-test difference is plotted against 731 
–log of the P value. The blue lines show the cut-off for significance as defined by the 732 
SAM. Integrin-β3 (Itgb3) as well as all detected tubulins (Tub) have been highlighted 733 
as red points. 734 
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C) Adhesome samples from β3WT and β3HET endothelial cells adhered to fibronectin. 735 
Samples were western blotted for integrin-β3 (Itgb3), α-tubulin and heat shock protein 736 
70 (Hspa1a). Blot shown is representative of the 5 individual experiments that are 737 
quantified in the bar graph below. Bars = mean (±SEM) relative α-tubulin levels 738 
normalised to Hspa1a levels.  739 
 740 
Figure 3. Analysis of microtubules in β3WT, β3HET and β3NULL endothelial 741 
cells. 742 
A) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin coated 743 
coverslips for 90 minutes before being PHEMO fixed and immunostained for α-tubulin 744 
(green). Nuclear (DAPI-blue) and Phallodin (F-actin - red) stains were also used. 745 
Inverted black and white images of α-tubulin and F-actin are shown below the three-746 
colour overlays. Scale bar = 10µm.  747 
B) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin for 90 748 
minutes before being lysed and western blotted for Integrin-β3 (Itgb3), α-tubulin and 749 
Gapdh (as a loading control). 750 
C) Left β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin 751 
coated coverslips for 90 minutes before being methanol (-20°C) fixed and 752 
immunostained for α-tubulin and talin-1. The number of microtubules that terminated 753 
(overlapping staining) at a talin-1 containing focal adhesion were counted for each 754 
genotype (n=15 cells per genotype, from 3 independent experiments). Right β3 WT, 755 
HET and NULL ECS were transfected with paxillin-GFP and left to recover overnight. 756 
The cells were then adhered to fibronectin coated coverslips and allowed to recover 757 
for 3 hours before being treated with 100 nM SiRTubulin and 1 µM verapamil overnight. 758 
The next day, fresh media containing SiRTubulin and verampamil (same dose) was 759 
added and cells were imaged every minute for 30 minutes (n=3 cells per genotype, 760 
from 3 independent experiments). Areas of adhesive fronts were assessed by 761 
measuring the growth of paxillin-GFP positive areas between the 1st and 30th image. 762 
The number of microtubules that entered the adhesive front was quantified to give the 763 
number of microtubules entering lamellipodia relative to the area of adhesive fronts for 764 
each cell.  765 
D) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin overnight. 766 
Migration speed of individual cells was measured over 15 hours using the MTrackJ 767 
plugin for ImageJ whilst under the influence of the indicated MTA. Migration speeds 768 
are shown as a percentage of the speed of the corresponding genotype under DMSO 769 
(vehicle) treatment (n³46 cells per genotype, from 4 independent experiments). 770 
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E) β3flox/flox Tie1Cre positive (pos) and negative (neg) animals were injected 771 
subcutaneously with 1X106 CMT19T lung carcinoma cells and then treated with vehicle 772 
(veh), or Eribulin (Eri). Bar graph shows mean (±SEM) tumour volumes (n³6; from 2-773 
3 independent experiments for each treatment condition) at the end of the experiment. 774 
Micrographs (below) show representative tumours. Scale bars = 5mm. 775 
F) After excision, tumours from β3flox/flox Tie1Cre positive (pos) and negative (neg) 776 
animals were processed and CD31 staining was assessed in vessel hotspots (see 777 
materials and methods) to measure vascular density. Bars = mean (±SEM) vessel 778 
number per mm2 (n=5 sections from each genotype, taken over 2-3 independent 779 
experiments for each treatment condition). Micrographs (below) show representative 780 
images of sections stained for alpha smooth muscle actin (αSMA=green), CD31 (red), 781 
DAPI (blue). Dotted white line indicates border of tumour and surrounding connective 782 
tissue. Scale bars = 100µm. 783 
 784 
Figure 4. Analysis of microtubule stability in β3WT, β3HET and β3NULL 785 
endothelial cells. 786 
A) Top β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin 787 
coated coverslips for 75 minutes at 37°C before being moved to ice for 15 minutes. 788 
Soluble tubulin was then washed out using PEM buffer (see materials and methods) 789 
before fixing with -20°C methanol (Note: this protocol leads to nuclear auto-fluorescent 790 
background in all three channels used). Immunostaining was carried out for α-tubulin 791 
(green) and Talin-1 (Tln1-red). DAPI (blue) was used as a nuclear stain. Images shown 792 
are representative of the data shown in the bar graph shown below. Scale bar = 5 µm. 793 
Bottom dot plots = mean (±SEM) number of cold-stable microtubules per cell (n ³ 300 794 
cells per genotype, from 3 independent experiments). 795 
B) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin for 75 796 
minutes at 37°C before being moved to ice for 15 minutes. Cold-soluble tubulin (Left 797 
blot) was then washed out using PEM buffer and western blotted for α-tubulin and 798 
Gapdh (as a loading control). Cold-insoluble tubulin (Middle blot) from the same cells 799 
was obtained by then lysing the remaining cells and western blotting for α-tubulin and 800 
Gapdh (as a loading control). Right bar chart  Bars = mean (±SEM) relative cold-801 
soluble and cold-insoluble α-tubulin levels for each genotype. Data are representative 802 
of 4 independent experiments. * indicates statistical significance compared to WT 803 
(P<0.05). 804 
 805 
 806 
 
23 
Figure 5. Microtuble stability in endothelial cells is regulated by Itgb3, Rcc2, 807 
Anxa2, and Rac1.  808 
A) β3WT ECs were transfected with control pool (CP) or Rcc2 smart pool siRNA and 809 
allowed to recover for 48 hours. They were then adhered to fibronectin coated 810 
coverslips for 75 minutes at 37°C before being moved to ice for 15 minutes. Soluble 811 
tubulin was then washed out using PEM buffer before fixing with -20°C methanol. 812 
Immunostaining was carried out for α-tubulin to allow counting of the number of cold 813 
stable microtubules per cell. Left Western blot showing representative Rcc2 814 
knockdown. Gapdh is shown as a loading control. Right Bars = mean (±SEM) number 815 
of cold stable microtubules shown as a percentage relative to CP treated cells (n ³ 455 816 
cells per condition, from 3 independent experiments). 817 
B) β3WT ECs were transfected with control pool (CP) or Anxa2 smart pool siRNA and 818 
allowed to recover for 48 hours. They were then adhered to fibronectin coated 819 
coverslips for 75 minutes at 37°C before being moved to ice for 15 minutes. Soluble 820 
tubulin was then washed out using PEM buffer before fixing with -20°C methanol. 821 
Immunostaining was carried out for α-tubulin to allow counting of the number of cold 822 
stable microtubules per cell. Top Western blot showing representative Anxa2 823 
knockdown in 3 separate samples. Bottom Left Bars = mean (±SEM) Anxa2 824 
knockdown shown as a percentage relative to CP treated cells. Samples have been 825 
normalised to Hspa1a. Bottom Right Bars = mean (±SEM) number of cold stable 826 
microtubules shown as a percentage relative to CP treated cells (n³450 cells per 827 
condition, from 3 independent experiments). 828 
C) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin coated 829 
coverslips for 60 minutes at 37°C before being treated with DMSO (control) or 50 µM 830 
NSC23766 and incubated at 37°C for a further 15 minutes. Coverslips were moved to 831 
ice for 15 minutes. Soluble tubulin was then washed out using PEM buffer before fixing 832 
with -20°C methanol. Immunostaining was carried out for alpha-tubulin to allow 833 
counting of the number of cold stable microtubules per cell. Bars = mean (±SEM) 834 
number of microtubules per cell shown as a percentage relative to DMSO treated 835 
controls (n=218 cells per condition, from 2 independent experiments). 836 
D) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin for 90 837 
minutes before being lysed and western blotted for Integrin-β3 (Itgb3), Rac1 and 838 
Hspa1a (as a loading control).  Blot shown is representative of 3 individual 839 
experiments. 840 
E) β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin coated 841 
plates for 90 minutes before being lysed in MLB (see materials and methods). GTP-842 
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Rac1 and bound proteins were extracted from cleared MLB using PAK-1 PBD 843 
magnetic beads at 4°C for an hour before being western blotted for Itga5, Itgb3, Rcc2, 844 
Anxa2 and Rac1. Blot is representative of at least 3 independent experiments Right 845 
Bars = mean (±SD) level of association of the indicated protein with GTP-Rac1, shown 846 
relative to β3WT associations (and normalized to the level of active Rac1 pulled down).  847 
Results are from at least 3 independent experiments. 848 
F) β3WT, β3HET and β3NULL endothelial cells were transfected with a Raichu-Rac1 849 
biosensor.  After 48 hours, cells were adhered to fibronectin coated plates for 90 850 
minutes, then fixed in PFA.  Left FRET-efficiency was measured as described in 851 
materials and methods.  Graph shows mean FRET efficiencies (±SEM) (n=17 cells per 852 
genotype; 2 independent experiments).  Right Representative images showing spatial 853 
distribution of Rac1 FRET efficiency in β3WT, β3HET and β3NULL endothelial cells 854 
(white stars indicate cytoplasmic localisation of active Rac1 in β3HET and β3NULL). 855 
Scale bar = 5µm. 856 
 857 
Expanded View Figure Legends 858 
Figure EV1. A Schematic demonstrating how figure 3C (right) was calculated. The 859 
yellow line indicates the edge of Pxn-GFP (green) positive areas at 0 minutes and the 860 
blue line indicates the edge at the end of 30 minutes. Microtubules were labelled red 861 
with SiR Tubulin. Scale bar = 5 μm. 862 
 863 
Figure EV2. β3WT, β3HET and β3NULL endothelial cells were adhered to fibronectin 864 
overnight. Migration speed of individual cells was measured over 15 hours using the 865 
MTrackJ plugin for ImageJ whilst under the influence of the indicated MTA.  Bars = 866 
mean migration speed (±SEM) (n³46 cells per genotype, from 4 independent 867 
experiments). 868 
 869 
Figure EV3 Top β3NULL endothelial cells were transfected with a full-length human 870 
β3-integrin (hβ3) cDNA expression construct or an empty vector (EV) control and 871 
western blotted for β3-integrin (β3NULL parent cells shown for comparison). Bottom 872 
β3NULL+EV or β3NULL+hβ3 endothelial cells were adhered to fibronectin coated 873 
coverslips for 75 minutes at 37°C before being moved to ice for 15 minutes. Soluble 874 
tubulin was then washed out using PEM buffer (see materials and methods) before 875 
fixing with -20°C methanol. Immunostaining was carried out for α-tubulin (green) and 876 
Talin-1 (Tln1-red). DAPI (blue) was used as a nuclear stain. Images shown are 877 
representative of the data shown in the bar graph above. Bars = mean (±SEM) number 878 
of cold-stable microtubules per cell. Scale bar = 5 µm. (n=96 cells per genotype). 879 
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Figure EV4. Top β3WT ECs were transfected with control pool (CP), Anxa2 smart pool 880 
siRNA, Rcc2 smart pool siRNA, or both and allowed to recover for 48 hours. They were 881 
then adhered to fibronectin coated coverslips for 75 minutes at 37°C before being 882 
moved to ice for 15 minutes. Soluble tubulin was then washed out using PEM buffer 883 
before fixing with -20°C methanol. Immunostaining was carried out for α-tubulin 884 
(green) and Talin-1 (Tln1-red). DAPI (blue) was used as a nuclear stain. Scale bar = 885 
5µm.  Bottom β3WT, β3HET and β3NULL cells were adhered to fibronectin coated 886 
coverslips for 60 minutes at 37°C before treated with DMSO or 50 µM NSC23766 and 887 
incubated at 37°C for a further 15 minutes.  Cells were then moved to ice for 15 888 
minutes. Soluble tubulin was washed out using PEM buffer before fixing with -20°C 889 
methanol. Immunostaining was carried out for α-tubulin (green) and Talin-1 (Tln1-red). 890 
DAPI (blue) was used as a nuclear stain. Scale bar = 5 µm. 891 
 892 
Figure EV5. Top β3WT endothelial cells were transfected with control pool (CP), 893 
Anxa2, or Rcc2 smart pool siRNA and allowed to recover for 48 hours. Cells were then 894 
adhered to fibronectin coated coverslips for 60 minutes at 37°C before treated with 895 
DMSO (veh) or 50 µM NSC23766 (+) and incubated at 37°C for a further 15 minutes. 896 
Coverslips were moved to ice for 15 minutes. Soluble tubulin was then washed out 897 
using PEM buffer before fixing with -20°C methanol. Immunostaining was carried out 898 
for alpha-tubulin to allow counting of the number of cold stable microtubules per cell. 899 
Bars = mean (±SEM) number of microtubules per cell shown as a percentage relative 900 
to the CP/veh control (n=100 cells per condition, from 2 independent experiments). 901 
Scale bar = 5 µm. 902 










